Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
3 reports, 3 independent
Updated Sep 5
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novartis entered a licensing deal with Arrowhead Pharmaceuticals to develop a treatment for Parkinson’s Disease.Sub-event
Novartis and Arrowhead collaborate on drug development, granting Novartis exclusive rights to ARO-SNCA.1 source
Keep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
- Partnership expands Novartis's oncology pipeline.
- Novartis operated through a wholly owned subsidiary in India on July 1, 2026.
- Novartis reaches an agreement that unlocks Alteogen's technology for use in injections.
- Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.
Coverage
Newest first; wire copies grouped- Motley FoolWhy Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal The deal opens up the possibility of future collaboration. Arrowhead moved a step closer to its aim of moving products into c
- GuruFocus.comArrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits This article first appeared on GuruFocus. Sep 3 - Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw its shares surge more than 5% on T
- Zacks Small Cap ResearchARWR: Signs Collaboration Agreement with Novartis with $200 Million Upfront… By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Signs Collaboration Agreement with Nova